Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03936218
Other study ID # EF 161
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 30, 2020
Est. completion date June 30, 2025

Study information

Verified date May 2024
Source Eurofarma Laboratorios S.A.
Contact Gleyce Lima
Phone 55 11 5090 8411
Email gleyce.lima@eurofarma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A two arm, multi centric, randomized, open label, parallel, two doses pharmacodynamics study in patients with advanced prostate cancer.


Description:

A phase III, two arm, multi centric, randomized, open label, parallel, two doses pharmacodynamics study in patients with advanced prostate cancer. Each patient will have 25 visits total. Total duration of the study will be 183 days (including up to 14 days of screening).


Recruitment information / eligibility

Status Recruiting
Enrollment 94
Est. completion date June 30, 2025
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male patient with age of 18 to 75 years (Both inclusive) 2. Body mass index (BMI) between 18.5 and 30 kg/m². (Both inclusive) 3. Patient with a confirmed advanced prostatic adenocarcinoma. (TNM stage III or IV or recurrent metastatic disease) who are scheduled to start Goserelin therapy as per Investigator discretion. Note: Stage III (T1-T2, N0, M0, PSA level is 20 or more, Grade Group 1-4 or T3--T4, N0, M0, any PSA, Grade Group 1-4 or any T, N0, M0, any PSA, Grade Group 5). Stage IV (any T, N1, M0, any PSA, any Grade Group or any T, N0, M1, any PSA, any Grade Group) 4. Serum testosterone level >2.5 ng/mL for age of 20 to 49 (both inclusive) and >1.9 ng/mL for age = 50 at screening. (Screening sample for Serum testosterone level should be taken before 10:00 am in the morning). 5. Patient must be able to give informed consent for participation in the trial. 6. Eastern Cooperative Oncology Group (ECOG) performance status = 2. 7. Adequate bone marrow function, renal function, liver function. 8. Patient should have recovered from any toxic effects of previous chemotherapy as judged by the Investigator. 9. Patients with life expectancy of at least 1 year as judged by the Investigator. 10. Patient or his partner willing to use an effective method as mentioned below of contraception during the study: - Tubal sterilization (tubal ligation performed more than one month before Study Day 1; transcervical tubal occlusion procedure performed more than six months before Study Day 1) - Barrier method (cervical cap, diaphragm, contraceptive sponge, vaginal spermicide, female condom, or male condom) - Two barrier methods used together (cervical cap, diaphragm, contraceptive sponge, or vaginal spermicide plus a male or female condom) Absolute sexual abstinence (no sexual intercourse or genital contact with a female partner). If the patient becomes sexually active during the study, then he is required to use a double barrier method of contraception. Exclusion Criteria: 1. Evidence of severe urinary tract obstruction with anticipated urinary retention, in the opinion of the Investigator, taking into account medical history, clinical observations and symptoms. 2. Patients who are scheduled to receive any chemotherapy/radiotherapy in addition to goserelin. 3. Patients who are already on GnRH receptor agonist or antagonist therapy directed for prostate cancer. 4. Patients who have previously failed on GnRH receptor agonist or antagonist therapy for prostate cancer. 5. Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, or any degree (proven or suspected) of brain or leptomeningeal involvement (past or present) or symptomatic pulmonary lymhangitic spread. Patients with discrete pulmonary parenchymal metastases are eligible, provided their respiratory function is not compromised as a result of disease. 6. Patients who are intended to be started on any medication apart from study drug that can have impact on any of the study endpoints. 7. Patients with spinal cord compression (in the opinion of the Investigator), taking into account medical history, clinical observations and symptoms. 8. Excruciating, severe bone pain which is due to extensive metastatic osseous deposits. 9. Patient has "currently active" second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy >5 years previously and have no known evidence of residual or recurrent disease. 10. Patients with confirmed signs or symptoms related to cerebral metastasis or radiographically confirmed brain metastasis. 11. Patients with a clinically significant medical condition other than advanced prostate cancer including but not limited to renal, hepatic, gastrointestinal, endocrine, cardiovascular, neurological or psychiatric disease, alcohol or substance abuse, or any other condition that may affect the patient's health or the outcome of the trial as judged by the investigator. 12. Patients with a known hypersensitivity to GnRH, GnRH-agonist analogues or any of the components in IMP. 13. History of orchiectomy, adrenalectomy or hypophysectomy. 14. Patients receiving anticoagulation medications. 15. Patients with uncontrolled diabetes mellitus (HbA1c > 8 % as per ADA) at randomization (those who have controlled blood sugar (fasting) will be eligible for randomization) 16. Uncontrolled hypertension (systolic blood pressure [BP] >140 or diastolic BP >90mm Hg) or uncontrolled cardiac arrhythmias. (Patients with hypertension controlled by antihypertensive therapies are eligible). 17. Patients with a QTc>450ms on the ECG at screening. 18. History of clinically significant cardiovascular disorder. 19. Use of any recreational drugs (cocaine, amphetamines, barbiturates, benzodiazepines, cannabinoids and morphine) or history of drug or alcohol abuse within the past 1 year, as judged by the Investigator, or a positive result on the urine drug/alcohol screen which is not consistent with current medical treatment. 20. Concomitant use of medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics. 21. A positive hepatitis screen including hepatitis B surface antigen or HCV antibodies. 22. Patients who test positive for HIV and/or syphilis. 23. The receipt of an investigational product, or participation in a drug research study within a period of 30 days prior screening or 5 half-lives within the last dose of investigational product, whichever is longer. Current use of any drugs that are known to interfere with goserelin metabolism or to cause a drug-drug interaction. 24. Donation / loss of blood/plasma or blood product (without replenishment) (1 unit or 350 mL) within 180 days prior to receiving the first dose of study medicine. 25. Patients with a mental incapacity, unwillingness, or language barrier that precludes the ability to understand or cooperate with study procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Inj. Goserelin (Test) Subcutaneously
10.8 mg, subcutaneously at every 3 month
Inj. Zoladex (Reference) Subcutaneously
10.8 mg, Subcutaneously at every 3 month

Locations

Country Name City State
India Mahatma Gandhi Cancer Hospital & Research Institute Visakhapatnam Andhra Pradesh

Sponsors (1)

Lead Sponsor Collaborator
Eurofarma Laboratorios S.A.

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate and compare the pharmacodynamics of test product against reference product and establish non inferiority. Proportion of patients achieving castrate level of serum testosterone (Serum testosterone = 0.5 ng/ml) at the end of 24 weeks 24 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06006104 - Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT02234089 - Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Completed NCT01078545 - Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) N/A
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Recruiting NCT05942001 - Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1
Active, not recruiting NCT04117594 - Whole Body Magnetic Resonance Imaging Study
Not yet recruiting NCT06369246 - PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer Phase 2
Completed NCT01383863 - A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
Completed NCT03651271 - Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer Phase 2
Active, not recruiting NCT05590793 - Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Phase 3
Recruiting NCT06095089 - A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer Phase 1
Active, not recruiting NCT02362620 - PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
Active, not recruiting NCT02787837 - PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
Recruiting NCT05800665 - A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer Phase 1
Recruiting NCT03938649 - SRAM study_Postate Cancer Phase 2
Completed NCT00871585 - Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide N/A
Active, not recruiting NCT02922218 - PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
Not yet recruiting NCT06335914 - Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer N/A
Terminated NCT03577028 - Study of HPN424 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Terminated NCT03971110 - A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. Phase 4